

Faculty Listing and Biographies

Paul G. Richardson, MD—Program Chair

RJ Corman Professor of Medicine, Harvard Medical School; Clinical Director, Jerome Lipper Center for Multiple Myeloma, Dana-Farber Cancer Institute; Boston, Massachusetts

Dr. Paul Richardson received his medical degree from the Medical College of St. Bartholomew's Hospital in London, United Kingdom. His postdoctoral training included internship in the departments of medicine and surgery at St. Bartholomew's Hospital; residency in the department of medicine at Newcastle University School of Medicine; appointment as chief resident in medical oncology at the Royal Marsden Hospital in London and Surrey; and additional residency training at the Beth Israel Hospital in Boston, Massachusetts. He completed fellowships in hematology/oncology and medical oncology at Tufts University School of Medicine, Baystate Medical Center, and Harvard Medical School, Dana-Farber Cancer Institute (DFCI) before coming on staff at DFCI.

Dr. Richardson currently holds leadership positions in several professional bodies and serves on the editorial board of the *Journal of Clinical Oncology*, the *Journal of Oncology*, *The Oncologist*, *Clinical Cancer Research*, and the *British Journal of Haematology*. He is the prior chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core, a position he held for 5 years as a founding member and as part of a rotating tenure, and for which he continues to serve on the Steering Committee and Project Review Committee. He now chairs the newly formed Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALGB). His honors include several Massachusetts General Hospital, Brigham and Women's Hospital, and Dana-Farber Partners in Excellence Awards; the Brigham and Women's Hospital Teaching Scholars Award; the Tisch Outstanding Achievement Award for Clinical Research; and the DFCI's George Canellos Award for Excellence in Clinical Research and Patient Care. For his contributions in hematology and oncology, and in particular myeloma, he was awarded an honorary fellowship of the Royal College of Physicians (FRCP) in 2009, and he was also more recently a co-recipient of the prestigious Warren Alpert Prize in 2012 for his role in the development of bortezomib as a first-in-class proteasome inhibitor.

Dr. Richardson has published more than 250 original articles, and more than 170 reviews, chapters, and editorials in leading peer-reviewed journals including the *New England Journal of Medicine*, *Blood*, *Journal of Clinical Oncology*, *Leukemia*, *Clinical Cancer Research*, and *British Journal of Haematology*. His primary research interest is in novel therapies, and he has been a leader in the clinical development of bortezomib, lenalidomide, and pomalidomide. Currently, he is leading multiple efforts studying the use of combination therapies in relapsed and refractory myeloma, an area of primary interest to him, and he has pioneered the development of lenalidomide, bortezomib, and dexamethasone (so-called RVD), which is now one of the most widely used combinations nationwide in the upfront treatment of myeloma. He is serving as principal investigator for several clinical

trials relating to other areas of myeloma treatment, including the use of combination therapies in earlier disease that are designed to target resistance and reduce toxicity.

Faith Davies, MBBCh, MRCP, MD, FRCPath

Senior Cancer Fellow, Cancer Research UK; Consultant Hematologist, Institute of Cancer Research, Royal Marsden Hospital; London, United Kingdom

Faith Davies qualified as a doctor at the University of Wales College of Medicine in Cardiff; she completed general medical training in Cardiff and Birmingham and hematology specialist training in Leeds and London, United Kingdom. During this time she also undertook research at the University of Leeds and the Dana-Farber Cancer Institute in Boston, Massachusetts, into the biology and treatment of multiple myeloma, concentrating on potential new drugs, new genetic technologies, and their application to myeloma.

Dr. Davies is a member of the British Society of Haematology and the American Society of Hematology. Additionally, she holds positions of prominence with several other professional bodies, including chair of the UK (National Cancer Research Institute) NCRI myeloma subgroup and the UK Myeloma Forum and member of the Myeloma UK Advisory Panel.

Dr. Davies has authored more than 150 publications in peer-reviewed journals and contributed to several book chapters and reviews on myeloma. She is also a reviewer for a number of international journals and grant-giving bodies. An active researcher, Dr. Davies is principal investigator on a number of phase 1, 2, and 3 clinical trials, including those run by the UK Medical Research Council and the National Cancer Research Institute (Myeloma IX and Myeloma XI). She has received funding for her research from Cancer Research UK, the Department of Health, the Leukaemia Research Fund, the Kay Kendall Leukaemia Fund, and the British Society for Haematology. Dr. Davies combines clinical work on hematologic malignancies with laboratory-based research concentrating on targeted approaches to therapy that are based on a sound knowledge of disease biology. Her laboratory is investigating targeting intracellular protein handling in myeloma.

Rafael Fonseca, MD

Getz Family Professor of Cancer, Mayo Clinic in Arizona, Scottsdale, Arizona

Dr. Rafael Fonseca received his medical degree from the University of Anahuac School of Medicine in Mexico City, Mexico. He completed a residency in internal medicine at the University of Miami in Florida and a fellowship in hematology/oncology at the Mayo Clinic in Rochester, Minnesota.

Dr. Fonseca is chair of the department of internal medicine and the Getz Family Professor for Cancer at the Mayo Clinic in Arizona, where he is also a member of the executive operations team. He has coauthored a number of articles for peer-reviewed journals.

Dr. Fonseca and his laboratory are focused on the understanding of myeloma and Waldenström macroglobulinemia with a particular emphasis on the genetic changes that characterize these diseases. His particular interest is in the development of novel therapeutics based on the knowledge generated from genomic research.

Gregory J. Orloff, MD
Virginia Cancer Specialists Fairfax, Virginia

Gregory J. Orloff, MD, received his medical degree from the Yale University School of Medicine where he was also selected as a member of the Alpha Omega Alpha honor society. He completed his medical internship, residency, and hematology/oncology fellowship at the Brigham and Women's Hospital and the Dana-Farber Cancer Institute in Boston, Massachusetts. Dr. Orloff was also a Howard Hughes Medical Institute Research Fellow at the Brigham and Women's Hospital. At the conclusion of his training, he joined the faculty in the hematology/oncology division at the Brigham and Women's Hospital at Harvard Medical School.

Dr. Orloff is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society of Bone Marrow Transplantation. Dr. Orloff has been recognized as a Best Doctor by *Washingtonian* magazine for more than 10 years, and he has also been featured on the prestigious Castle Connolly Top Doctors list.

Dr. Orloff joined Virginia Cancer Specialists (VCS) in 1995. Since joining, he has co-directed the Stem Cell Transplant Program in partnership with INOVA Fairfax Hospital. He is the past section chief of hematology/oncology at INOVA Fairfax Hospital. Virginia Cancer Specialists recently became a member of the Multiple Myeloma Research Consortium (MMRC) for which Dr. Orloff is the site director and principle investigator.

Donna E. Reece, MD
Princess Margaret Hospital Toronto, Ontario, Canada

Dr. Donna Reece is professor and director of the Program for Multiple Myeloma and Related Diseases in the department of medical oncology and hematology at Princess Margaret Hospital/University of Toronto. She was awarded the David and Molly Bloom Chair in Multiple Myeloma Research at Princess Margaret Hospital/University Health Network in November 2009.

She graduated as valedictorian with a medical degree from Baylor College of Medicine, Houston, Texas. She completed an internship in internal medicine at the University of Colorado Affiliated Hospitals, a residency and chief residency in internal medicine at Jewish Hospital, St. Louis, and a fellowship in hematology/oncology at Barnes Hospital, Washington University, St. Louis, Missouri. She was a fellow and later a leukemia/stem cell

transplant physician at Vancouver General Hospital/University of British Columbia for over 10 years.

Dr. Reece then served as director of the Outpatient Leukemia/Stem Cell Transplant Program, and later interim director, of the Blood and Marrow Transplant Program of the Markey Cancer Center at the University of Kentucky, Lexington, Kentucky until her appointment to Princess Margaret Hospital in Toronto in 2001.

Dr. Reece is currently the chair of the Multiple Myeloma Clinical Trials Group of the National Cancer Institute of Canada, member of the US National Cancer Institute Hematology Steering Committee, member of the Scientific Advisory Board of the International Myeloma Foundation, co-chair of the High Risk Myeloma Core Committee of the MMRC (Multiple Myeloma Research Consortium). She has played an instrumental role in establishing the Myeloma Canada Research Network (MCRN). She also served for 10 years as co-chair of the Myeloma Working Committee of the International Center for Blood and Marrow Transplant Research (CIBMTR). Her career focus has been in the areas of hematopoietic stem cell transplantation, lymphoid malignancies, and, in particular, plasma cell dyscrasias. She has conducted many clinical trials and published numerous articles in these areas.

Robert M. Rifkin, MD, FACP

Clinical Associate Professor of Medicine, Department of Internal Medicine, Division of Medical Oncology, University of Colorado, Denver, Denver, Colorado

Robert M. Rifkin is clinical associate professor of medicine in the department of internal medicine, division of medical oncology at the University of Colorado, Denver. Dr. Rifkin's clinical specialties include hematology, oncology, blood cancer, and coagulation. His research focuses on the development of new treatments for patients with multiple myeloma. He also focuses his efforts toward fostering the introduction of biosimilars into research and clinical practice in the United States, which will result in cost reduction of health care and improved patient access to complex biologics. His research efforts have been highlighted in more than 100 publications.

Certified by the American Board of Internal Medicine in internal medicine, medical oncology, and hematology and a fellow of the American College of Physicians, Dr. Rifkin holds key positions with a number of professional organizations. He serves as the myeloma disease lead and associate chair of the US Oncology Hematology Research Committee and is an inspector for the Foundation for Accreditation of Cellular Therapy. Dr. Rifkin also serves as the medical director of biosimilars for McKesson Specialty Health and is an executive board member of the Patient Advocate Foundation and the National Patient Advocate Foundation.

Dr. Rifkin has received many honors, including the National Marrow Donor Program Trailblazer Award (1998), selection to the 5280 Magazine list of Top Doctors, Hematology and Oncology (2000, 2004), the Leukemia & Lymphoma Society's Man of the Year (Colorado) award (2001), and selection to America's Top Physicians list (2005, 2008, 2009).

Dr. Rifkin received a medical degree from the University of Colorado School of Medicine in Denver. He completed an internship and residency in internal medicine at Presbyterian/St. Luke's Medical Center in Denver and a medical oncology/hematology fellowship at the University of Arizona Health Sciences Center in Tucson.

Pieter Sonneveld, MD, PhD
Professor of Hematology and Chairman, Erasmus Medical Center Cancer Institute,
Rotterdam, The Netherlands

Pieter Sonneveld, MD, PhD, was born in The Netherlands. He received his medical degree from Erasmus University in Rotterdam, The Netherlands in 1977. In 1980 he completed a PhD thesis on the pharmacology of adriamycin in acute leukemia at the University of Leiden. He subsequently received a Fogarty Fellowship and worked 2 years at the National Cancer Institute in the United States.

Dr. Sonneveld's current position is professor of hematology and head of the department of hematology of the Erasmus Medical Center Cancer Institute and chairman of the Cancer Center and Erasmus University, Rotterdam. He coordinates a research team of people working on the molecular and clinical aspects of drug resistance mechanisms in multiple myeloma.

He is co-chair of the HOVON Myeloma Trialist Group and he coordinates clinical trials in multiple myeloma, lymphoma, and leukemia in The Netherlands. He currently is treasurer of the HOVON group, Executive Board member and treasurer of the European Hematology Association (EHA), and chair of the European Myeloma Network (EMN). Within EMN, he coordinates a cooperative network for clinical trials and scientific workshops in Europe. He serves on the scientific advisory boards of the International Myeloma Foundation and Multiple Myeloma Research Foundation and has been a member of the editorial boards of medical journals including *Blood*, *Leukemia*, and *Haematologica*. He is currently section editor for multiple myeloma of *Haematologica*. Dr. Sonneveld has authored more than 300 scientific publications and several book chapters.